Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy

Groupe Hospitalier Pitie-Salpetriere

Status and phase: Unknown; Phase 2

Conditions: Supranuclear Palsy, Progressive

Treatments: Drug: donepezil

Study type: Interventional

Funder types: Other

Identifiers

NCT00139373

RBM0323

Details and patient eligibility

About

The syndrome of distractibility is a behavioral disorder induced by a lesion or a dysfunction of the frontal lobe. This sign is frequent in patients with progressive supranuclear palsy (PSP), a neurodegenerative disorder with severe neuronal loss in the prefrontal cortex and cholinergic systems, in particular in the Meynert basalis nucleus. This could participate in the occurrence of the distractibility in these patients. The aim of this study is to evaluate the effect of the donepezil, an anticholinesterase, on the distractibility in PSP patients, by using oculomotor and neuropsychological assessments.

Enrollment: 16 estimated patients

Sex: All

Ages: 30 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with PSP
• Age > 30 years old
• Disease duration < 5 years
• Mini mental state (MMS) > 24
• Antisaccades %: 40-80%

Exclusion criteria

• Other parkinsonian syndromes
• MMS < 24

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind